GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Artificial Intelligence /Machine learning in GI Endoscopy

Machine learning in GI Endoscopy

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated November 1, 2025

Quick Answer

Machine learning (ML) has revolutionized gastrointestinal (GI) endoscopy by improving diagnostic precision, reducing variability, and streamlining workflows. ML algorithms analyze endoscopic images or videos to detect patterns, identify lesions, and assist in diagnosing, characterizing, or localizing GI diseases such as polyps, cancers, inflammatory bowel disease, and ulcers.


Machine learning (ML) has revolutionized gastrointestinal (GI) endoscopy by improving diagnostic precision, reducing variability, and streamlining workflows. ML algorithms analyze endoscopic images or videos to detect patterns, identify lesions, and assist in diagnosing, characterizing, or localizing GI diseases such as polyps, cancers, inflammatory bowel disease, and ulcers. This integration enhances lesion detection rates, predicts disease progression, and standardizes examination quality, reducing operator-dependent variability.

Key applications of ML in GI endoscopy include:

1. **Computer-Assisted Detection (CADe):** Identifying lesions such as polyps or bleeding during endoscopy.

2. **Computer-Assisted Diagnosis (CADx):** Characterizing and classifying lesions to aid in diagnosis.

3. **Therapeutic Assistance:** Supporting interventional decisions, such as predicting lymph node metastasis (LNM) in colorectal cancer (CRC) to reduce unnecessary surgeries.

4. **Technical Support:** Enhancing procedural performance, such as scope insertion guidance for more precise and comfortable colonoscopies.

Despite these advancements, challenges remain. High-quality, diverse, and annotated training datasets are essential, but current datasets often lack diversity, contain biases, and underrepresent rare diseases. Manual annotation is time-consuming, and low-quality images or artefacts can hinder accuracy. Additionally, balancing model accuracy with speed, cost, and computational efficiency is crucial.

Ethical and regulatory concerns, such as patient privacy, algorithmic bias, data security, and transparency, are significant barriers to adoption. Real-time deployment is also limited by technical infrastructure, false positives, and workflow disruptions.

Future success will require standardized protocols, clinician training, interdisciplinary collaboration, and advancements in explainable AI to build trust and ensure safe, effective integration of ML into GI endoscopy.

Related Q&A

AI and U.S. Healthcare Costs: NEJM Catalyst | July 2026

Introduction: Artificial intelligence is rapidly transforming healthcare through drug discovery, clinical decision support, remote monitoring, and administrative automation. While AI is widely expected to reduce healthcare costs, this perspective argues that current payment models and...

Large AI Models and Healthcare: Nature Medicine | June 2026

Introduction: Large frontier AI models such as GPT-5 and Gemini have achieved impressive results across numerous healthcare benchmarks. However, high benchmark scores alone may not reflect real-world clinical reliability. This study systematically evaluated the robustness...

AI Ethics From Silicon Valley to the Vatican: JAMA | July 2026

Introduction: Artificial intelligence is rapidly transforming medicine, but its influence extends far beyond healthcare. This JAMA AI Conversations article explores how AI ethics has become a global societal issue, engaging technology leaders, policymakers, healthcare professionals,...

Physician-Complementing AI in Oncology: The ASCO Post | June 2026

Introduction: Artificial intelligence is rapidly transforming oncology, evolving from image interpretation and pathology analysis to supporting complex clinical decision-making. This perspective argues that AI should enhance the capabilities of oncologists rather than replace their expertise....

AI-Based Clinical Trial End Points: A New Era in Drug Development: NEJM AI | July 2026

Introduction Clinical trial endpoints have traditionally relied on expert human interpretation, particularly for pathology-based outcomes. However, variability between observers, cost, and time remain important limitations. This NEJM AI perspective discusses how artificial intelligence is beginning...

Medical AI Assistant: Publication or Medical Device?: NEJM AI | July 2026

Introduction: As artificial intelligence becomes increasingly integrated into clinical practice, an important question arises: should AI assistants be regulated as medical devices or viewed as evidence-based clinical methodologies? This NEJM AI perspective proposes a new...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer